If you have chronic obstructive pulmonary disease (COPD), your airways may be inflamed. It may be hard to take deep breaths and get enough oxygen.

More people may be at risk for developing COPD due to exposure to environmental irritants, such as heat waves and air ...

Discover Verona Pharma's Q1 2025 earnings report, featuring Ohtuvayre's rapid adoption, sales milestones, and global expansion.

Increased perceived stress may cause worsened respiratory symptoms and decreased quality of life in people with chronic ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Researchers sought to determine the relationship among hospitalization for COPD exacerbation, AF burden, and risk for subsequent stroke.

The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

Increased perceived stress may cause worsened respiratory symptoms and decreased quality of life in people with chronic obstructive pulmonary disease (COPD), according to a new study.

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses exc ...

Increased perceived stress may cause worsened respiratory symptoms and decreased quality of life in people with chronic obstructive pulmonary disease ...